Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013
Key Highlights Kaigene grants Celltrion exclusive worldwide development and commercialization rights to KG013, while retaining an option to participate in co-marketing in South Korea under the agreement. KG013 is a next-generation, half-life-extended, fully human anti-APRIL monoclonal...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


